{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:07:58Z","timestamp":1789391278631,"version":"build-2803163510"},"reference-count":22,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Contemporary drug-eluting stents (DES) differ in antiproliferative drug, strut geometry, polymer, alloy, and drug release kinetics, and the independent association between the eluted drug and clinical outcomes remains uncertain. We compared outcomes among contemporary sirolimus-, zotarolimus-, and everolimus-eluting stents. Methods: This single-center retrospective cohort included 1940 patients who underwent percutaneous coronary intervention (PCI) between 2012 and 2021 with sirolimus- (n = 537), zotarolimus- (n = 400), or everolimus-eluting stents (n = 1003). The primary endpoint was target vessel failure (TVF), a composite of cardiac death, target vessel myocardial infarction (MI), or target vessel revascularization (TVR). The secondary endpoint was major adverse cardiovascular events (MACE), a composite of all-cause death, MI, or any revascularization. Stabilized inverse probability of treatment weighting (IPTW) based on pretreatment covariates and PCI era was used to address baseline and temporal differences; follow-up was censored at two years. Results: During a median follow-up of 731 days, weighted TVF rates were 5.4%, 7.7%, and 6.5% in the sirolimus, zotarolimus, and everolimus groups, respectively. Compared with sirolimus, TVF did not differ with zotarolimus (hazard ratio [HR] 1.38; 95% confidence interval [CI] 0.74\u20132.58) or everolimus (HR 1.19; 95% CI 0.70\u20132.02; overall p = 0.458). MACE also did not differ (overall p = 0.517). In complex PCI, TVF was higher with zotarolimus and everolimus than with sirolimus; however, event counts were small and the analyses were exploratory. Conclusions: In this observational cohort, no significant differences in mid-term outcomes were observed among the three drug-defined groups. Because drug type is closely intertwined with stent platform design, these findings should not be extrapolated to individual stent platforms. The exploratory complex-PCI subgroup finding requires confirmation in larger studies.<\/jats:p>","DOI":"10.3390\/jcm15187087","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:09:51Z","timestamp":1789387791000},"page":"7087","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Two-Year Clinical Outcomes of Contemporary Drug-Eluting Stents Grouped by Eluted Limus Agent: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"15","author":[{"given":"Donghyeon","family":"Joo","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital, 895 Muwang-ro, Iksan 54538, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0407-2568","authenticated-orcid":false,"given":"Jeong Tae","family":"Byoun","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital, 895 Muwang-ro, Iksan 54538, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7972-6223","authenticated-orcid":false,"given":"Jae Young","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital, 895 Muwang-ro, Iksan 54538, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]},{"given":"Sungho","family":"Jo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital, 895 Muwang-ro, Iksan 54538, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4911-8854","authenticated-orcid":false,"given":"Kyeong Ho","family":"Yun","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital, 895 Muwang-ro, Iksan 54538, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1210816","article-title":"Drug-eluting coronary-artery stents","volume":"368","author":"Stefanini","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/S0140-6736(16)31920-1","article-title":"Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in all-comers with coronary artery disease (BIO-RESORT): A three-arm, randomised, non-inferiority trial","volume":"388","author":"Kok","year":"2016","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.54912\/jci.2021.0006","article-title":"Clinical outcomes following SYNERGY stent implantation in a prospective all-comers registry","volume":"1","author":"Yun","year":"2022","journal-title":"J. Cardiovasc. Interv."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.54912\/jci.2022.0021","article-title":"Three-year clinical outcomes of a thin-strut biodegradable-polymer everolimus-eluting stent in patients with acute coronary syndrome","volume":"2","author":"Sim","year":"2023","journal-title":"J. Cardiovasc. Interv."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.54912\/jci.2024.0034","article-title":"Ultrathin bioresorbable polymer sirolimus-eluting Orsiro stents for complex percutaneous coronary intervention","volume":"4","author":"Jeon","year":"2025","journal-title":"J. Cardiovasc. Interv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.54912\/jci.2025.0015","article-title":"Three-year outcomes of a bioabsorbable-polymer sirolimus-eluting stent in patients with acute coronary syndrome in Korea","volume":"5","author":"Oh","year":"2026","journal-title":"J. Cardiovasc. Interv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.54912\/jci.2025.0027","article-title":"Comparison of biodegradable polymer sirolimus-eluting stent and durable polymer drug-eluting stent in real-world percutaneous coronary intervention","volume":"5","author":"Song","year":"2026","journal-title":"J. Cardiovasc. Interv."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/clinchem\/hvab278","article-title":"National Kidney Foundation Laboratory Engagement Working Group recommendations for implementing the CKD-EPI 2021 race-free equations for estimated glomerular filtration rate: Practical guidance for clinical laboratories","volume":"68","author":"Miller","year":"2022","journal-title":"Clin. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","article-title":"Efficacy and safety of dual antiplatelet therapy after complex PCI","volume":"68","author":"Giustino","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","article-title":"2017 cardiovascular and stroke endpoint definitions for clinical trials","volume":"137","author":"Hicks","year":"2018","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.jcin.2019.04.054","article-title":"Thin, very thin, or ultrathin strut biodegradable or durable polymer-coated drug-eluting stents: 3-year outcomes of BIO-RESORT","volume":"12","author":"Buiten","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e026041","DOI":"10.1161\/JAHA.122.026041","article-title":"Final 5-year report of the randomized BIO-RESORT trial comparing 3 contemporary drug-eluting stents in all-comers","volume":"11","author":"Ploumen","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1016\/j.jacc.2013.04.005","article-title":"Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting Resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial","volume":"61","author":"Tandjung","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jcin.2017.11.031","article-title":"5-year outcome following randomized treatment of all-comers with zotarolimus-eluting Resolute Integrity and everolimus-eluting PROMUS Element coronary stents: Final report of the DUTCH PEERS trial","volume":"11","author":"Zocca","year":"2018","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.jcin.2020.01.230","article-title":"Thin composite-wire-strut zotarolimus-eluting stents versus ultrathin-strut sirolimus-eluting stents in BIONYX at 2 years","volume":"13","author":"Buiten","year":"2020","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_16","first-page":"1","article-title":"Final 5-year report of BIONYX comparing the thin-composite wire-strut zotarolimus-eluting stent versus ultrathin-strut sirolimus-eluting stent","volume":"104","author":"Ploumen","year":"2024","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_17","first-page":"1399","article-title":"Three-year clinical outcome of biodegradable hybrid polymer Orsiro sirolimus-eluting stent and the durable biocompatible polymer Resolute Integrity zotarolimus-eluting stent: A randomized controlled trial","volume":"96","author":"Kim","year":"2020","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1161\/CIRCULATIONAHA.118.034456","article-title":"Newer-generation ultrathin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease: Meta-analysis of randomized trials","volume":"138","author":"Bangalore","year":"2018","journal-title":"Circulation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jcin.2021.09.028","article-title":"Differential effects of newer-generation ultrathin-strut versus thicker-strut drug-eluting stents in chronic and acute coronary syndromes","volume":"14","author":"Iglesias","year":"2021","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1016\/j.jcin.2020.09.014","article-title":"Target lesion failure with current drug-eluting stents: Evidence from a comprehensive network meta-analysis","volume":"13","author":"Taglieri","year":"2020","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.amjcard.2007.11.008","article-title":"Effect of percutaneous coronary intervention on coronary blood flow at rest in myocardial sites remote from the intervention site in patients with stable angina pectoris","volume":"101","author":"Manfrini","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11883-026-01455-7","article-title":"Exercise after coronary stenting: Potential effects on in-stent restenosis","volume":"28","author":"Spadafora","year":"2026","journal-title":"Curr. Atheroscler. Rep."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7087\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:48:51Z","timestamp":1789390131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":22,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15187087"],"URL":"https:\/\/doi.org\/10.3390\/jcm15187087","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]}}}